ProCE Banner Activity

CME

Moving Toward Precision Therapy for Patients With AML: Clinical Challenges and Future Directions

Multimedia

Watch this on-demand Webcast from the CCO AML satellite symposium at ASH 2018, featuring expert faculty Stéphane de Botton, MD, PhD, Mark J. Levis, MD, PhD, Farhad Ravandi, MD, Gary J. Schiller, MD, and Eunice S. Wang, MD, as they present the latest clinical advances in treatment strategies for patients with AML, including newly approved agents.

Physicians : maximum of 2.25 AMA PRA Category 1 {Credits}

Released: February 07, 2019

Expiration: February 06, 2020

No longer available for credit.

Share

Faculty

Farhad Ravandi

Farhad Ravandi, MD

Professor of Medicine
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Mark J. Levis

Mark J. Levis, MD, PhD

Professor of Oncology
Division of Hematologic Malignancies
Department of Oncology
Johns Hopkins University
Director, Adult Leukemia Service
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Gary J. Schiller

Gary J. Schiller, MD

Professor
Division of Hematology/Oncology
Department of Medicine
Director, Hematological Malignancy/Stem Cell Transplantation
David Geffen School of Medicine at UCLA
Los Angeles, California

Eunice S. Wang

Eunice S. Wang, MD

Chief, Leukemia/Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

This activity is supported by educational grants from

Actinium

Astellas Text

Boston Biomedical

Celgene

Daiichi Sankyo, Inc.

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with acute myeloid leukemia.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate the clinical data on prognostic or predictive molecular features or aberrations in AML and describe their clinical importance in terms of diagnosis, risk prediction, and therapeutic decisions
  • Assess the available evidence to optimally integrate antibody–drug conjugates and other antibody-based therapies in AML
  • Plan evidence-based therapeutic strategies using novel formulations and refinements of conventional chemotherapy
  • Develop personalized treatment plans for patients with newly diagnosed or relapsed/refractory AML with FLT3 or IDH1/2 mutations
  • Manage treatment-related toxicities associated with novel therapeutics

Disclosure

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

Farhad Ravandi, MD

Professor of Medicine
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Farhad Ravandi, MD, has disclosed that he has received consulting fees from Agios, Amgen, Ariad, Astellas, Jazz, and Orsenix and funds for research support from AbbVie, Amgen, Bristol-Myers Squibb, Seattle Genetics, and Xencor.

Faculty Disclosure

Primary Author

Mark J. Levis, MD, PhD

Professor of Oncology
Division of Hematologic Malignancies
Department of Oncology
Johns Hopkins University
Director, Adult Leukemia Service
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Mark J. Levis, MD, PhD, has disclosed that he has received consulting fees from Astellas, Daiichi, and Novartis.

Gary J. Schiller, MD

Professor
Division of Hematology/Oncology
Department of Medicine
Director, Hematological Malignancy/Stem Cell Transplantation
David Geffen School of Medicine at UCLA
Los Angeles, California

Gary J. Schiller, MD, has disclosed that he has received funds for research support from Agios, Amgen, Astellas, Celgene, Celator, Daiichi, Gilead Sciences, Incyte, Karyopharm, Kite, Onconova, OxiGene, and TrovaGene and holds ownership interests with Amgen, Novartis, and Pfizer.

Eunice S. Wang, MD

Chief, Leukemia/Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Eunice S. Wang, MD, has disclosed that she has received consulting fees from Amgen and Pfizer and fees for non-CME/CE services from Jazz and Novartis.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.

Terrence Fagan,

Associate Scientific Director

Terrence Fagan has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.

Instructions for Credit

Joint Accreditation Statement
In support of improving patient care, Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

The PIM planners and managers have nothing to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 2.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 07, 2019, through February 06, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the competence and performance of the multidisciplinary care team in applying the latest practice-changing developments to the clinical care of patients with acute myeloid leukemia.